Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer
The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers. Patient advocacy efforts are supported by Cancer ABCs.
Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer
An International Registry for Men with Advanced Prostate Cancer
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Fulfilling our mission of translating scientific discoveries to improved standards of care...
Learn MoreLearn More
Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.